INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 4,948	$ 22,626
Short-term bank deposits	16,517	7,167
Restricted cash and short term bank deposits	550	1,076
Marketable securities	21,636	22,250
Account receivable from the Office of the Chief Scientist	150	1,691
Other account receivable	981	2,058
Total current assets	44,782	56,868
LONG-TERM ASSETS:
Long-term deposits and restricted deposits	340	361
Severance pay fund	749	753
Property and equipment, net	10,170	10,173
Total long-term assets	11,259	11,287
Total assets	56,041	68,155
CURRENT LIABILITIES
Trade payables	1,835	3,268
Accrued expenses	$ 1,277	910
Deferred revenues		379
Advance payment from United Therapeutics		93
Other accounts payable	$ 1,500	1,533
Total current liabilities	$ 4,612	6,183
LONG-TERM LIABILITIES
Deferred revenues		2,468
Accrued severance pay	$ 861	859
Other long-term liabilities	1,219	502
Total long-term liabilities	$ 2,080	$ 3,829
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Share capital: Common stock $0.00001 par value: Authorized: 200,000,000 shares Issued and outstanding: 79,736,404 shares as of December 31, 2015, 78,771,905 shares as of June 30, 2015	$ 1	$ 1
Additional paid-in capital	196,929	195,303
Accumulated deficit	$ (148,349)	(138,511)
Receivables on account of shares		(790)
Other comprehensive income	$ 768	2,140
Total stockholders' equity	49,349	58,143
Total liabilities and stockholders' equity	$ 56,041	$ 68,155